Search Results - "Carvajal, Luis A."

E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression by Carvajal, Luis A, Hamard, Pierre-Jacques, Tonnessen, Crystal, Manfredi, James J

“…The p53 tumor suppressor protein is a transcription factor that exerts its effects on the cell cycle via regulation of gene expression. Although the mechanism…”
Get full text

Pharmacological inhibition of the transcription factor PU.1 in leukemia by Antony-Debré, Iléana, Paul, Ananya, Leite, Joana, Mitchell, Kelly, Kim, Hye Mi, Carvajal, Luis A, Todorova, Tihomira I, Huang, Kenneth, Kumar, Arvind, Farahat, Abdelbasset A, Bartholdy, Boris, Narayanagari, Swathi-Rao, Chen, Jiahao, Ambesi-Impiombato, Alberto, Ferrando, Adolfo A, Mantzaris, Ioannis, Gavathiotis, Evripidis, Verma, Amit, Will, Britta, Boykin, David W, Wilson, W David, Poon, Gregory Mk, Steidl, Ulrich

“…The transcription factor PU.1 is often impaired in patients with acute myeloid leukemia (AML). Here, we used AML cells that already had low PU.1 levels and…”
Get full text

p53 Promotes cell survival due to the reversibility of its cell-cycle checkpoints by Lukin, Dana J, Carvajal, Luis A, Liu, Wen-jun, Resnick-Silverman, Lois, Manfredi, James J

“…The tumor suppressor p53 (TP53) has a well-studied role in triggering cell-cycle checkpoint in response to DNA damage. Previous studies have suggested that…”
Get full text

Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy by Carvajal, Luis A., Steidl, Ulrich

“…Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular…”
Get full text

The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo by Hamard, Pierre-Jacques, Barthelery, Nicolas, Hogstad, Brandon, Mungamuri, Sathish Kumar, Tonnessen, Crystal A, Carvajal, Luis A, Senturk, Emir, Gillespie, Virginia, Aaronson, Stuart A, Merad, Miriam, Manfredi, James J

“…The p53 tumor suppressor is a transcription factor that mediates varied cellular responses. The C terminus of p53 is subjected to multiple and diverse…”
Get full text

Another fork in the road-life or death decisions by the tumour suppressor p53 by Carvajal, Luis A, Manfredi, James J

“…In response to cellular stress signals, the tumour suppressor p53 accumulates and triggers a host of antineoplastic responses. For instance, DNA damage…”
Get full text

Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity by Zhou, Xiaolei, Singh, Madhurendra, Sanz Santos, Gema, Guerlavais, Vincent, Carvajal, Luis A, Aivado, Manuel, Zhan, Yue, Oliveira, Mariana M S, Westerberg, Lisa S, Annis, D Allen, Johnsen, John Inge, Selivanova, Galina

“…The repression of repetitive elements is an important facet of p53's function as a guardian of the genome. Paradoxically, we found that p53 activated by MDM2…”
Get more information

IL1RAP potentiates multiple oncogenic signaling pathways in AML by Mitchell, Kelly, Barreyro, Laura, Todorova, Tihomira I, Taylor, Samuel J, Antony-Debré, Iléana, Narayanagari, Swathi-Rao, Carvajal, Luis A, Leite, Joana, Piperdi, Zubair, Pendurti, Gopichand, Mantzaris, Ioannis, Paietta, Elisabeth, Verma, Amit, Gritsman, Kira, Steidl, Ulrich

“…The surface molecule interleukin-1 receptor accessory protein (IL1RAP) is consistently overexpressed across multiple genetic subtypes of acute myeloid leukemia…”
Get full text

PB1889: KB‐LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3‐MUTATED R/R AML by Patel, Anand, Michaelis, Laura, Schiller, Gary, Swords, Ronan, Morris, Lawrence E., Carvajal, Luis A., Bray, Gordon, Olek, Elizabeth A., Cutler, Richard, Dimartino, Jorge, Stein, Eytan

Get full text

MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism by Ueda, Koki, Kumari, Rajni, Schwenger, Emily, Wheat, Justin C., Bohorquez, Oliver, Narayanagari, Swathi-Rao, Taylor, Samuel J., Carvajal, Luis A., Pradhan, Kith, Bartholdy, Boris, Todorova, Tihomira I., Goto, Hiroki, Sun, Daqian, Chen, Jiahao, Shan, Jidong, Song, Yinghui, Montagna, Cristina, Xiong, Shunbin, Lozano, Guillermina, Pellagatti, Andrea, Boultwood, Jacqueline, Verma, Amit, Steidl, Ulrich

“…MDMX is overexpressed in the vast majority of patients with acute myeloid leukemia (AML). We report that MDMX overexpression increases preleukemic stem cell…”
Get full text

Multivariate AB-BA crossover trial by Rodriguez-Carvajal, Luis A.

“…One way to analyze the AB-BA crossover trial with multivariate response is proposed. The multivariate model is given and the assumptions discussed. Two…”
Get full text

The Combination of Lanraplenib, a Selective SYK Inhibitor, and Gilteritinib, a FLT3 Inhibitor, Targets Aberrant Proliferation and Differentiation Blockade in Acute Myeloid Leukemia by Carvajal, Luis A., McKeown, Michael R., Hood, Tressa, Guo, Linlin, Lin, Charles Y., DiMartino, Jorge F.

“…Background: Acute myeloid leukemia (AML) is an aggressive disease characterized by uncontrolled clonal proliferation of poorly differentiated myeloid…”
Get full text

SYK Inhibitors, Entospletinib and Lanraplenib, Show Potent Anti-Leukemic Activity in Combination with Targeted Agents by Carvajal, Luis A., McKeown, Michael, Hood, Tressa, Kumar, Pavan, Saffran, Douglas C., DiMartino, Jorge

Get full text

Responses in patients with AML and treated with entospletinib monotherapy by Lin, Tara L., Cutler, Richard E., Olek, Elizabeth, Carvajal, Luis A., DiMartino, Jorge F., Walker, Alison R.

“…e19010 Background: AML is a disease defined by the acquisition of genetic lesions in normal hematopoietic stem cells and progenitors resulting in poorly…”
Get full text

Combined Single Cell Flow Cytometry and Imaging Analyses Reveal Immunomodulatory Effects Exerted By Targeted Phospho-SYK Inhibitors with Elevated Sensitivity in NPM1 Mutated AML by Robinson, Bridget A, Sergeev, Philipp, Kosaka, Yoko, Jacob, Thomas, Kaempf, Andy, Lind, Evan F., Tognon, Cristina, Carvajal, Luis A., DiMartino, Jorge F., Heckman, Caroline A., Vu, Tania Q

“…Acute myeloid leukemia (AML) is driven by genetic lesions that can result in addiction to signaling pathways that lead to aberrant proliferation and survival…”
Get full text

The Novel Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) Platform Identifies Synergistic Activity of Lanraplenib and Ruxolitinib in Hematological Malignancies by Pandey, Akanksha, Carvajal, Luis A., Boghossian, Andrew S, Rees, Matthew G, Ronan, Melissa M, Roth, Jennifer A, Hood, Tressa, Guo, Linlin, Hopkins, Tamara D, Obholzer, Nikolaus, McKeown, Michael R., DiMartino, Jorge F., Lin, Charles Y.

“…Background: Investigation of drug combinations across different contexts can provide useful insights on the anti-cancer mechanism and can ultimately lead to…”
Get full text

KB-Lanra 1001: A Phase 1b/2 Study of Safety, PK, PD, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib in Combination with the FLT3 Inhibitor Gilteritinib in FLT3-Mutated R/R AML by Arnan, Monteserrat, Patel, Anand Ashwin, Esteve, Jordi, Morris, Lawrence, Schiller, Gary J., Swords, Ronan T., Alonso-Dominguez, Juan M., Michaelis, Laura C., Daver, Naval, Carvajal, Luis A., Bray, Gordon, Olek, Elizabeth, Cutler, Richard E., DiMartino, Jorge F., Stein, Eytan M.

“…Background and Significance: FMS-like tyrosine kinase (FLT3)-mutation (FLT3 mut) in patients with newly diagnosed and relapsed/refractory (R/R) acute myeloid…”
Get full text

Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study by Carvajal, Luis A., Hood, Tressa, Bevan, Yana, Dillon, Richard, Potter, Nicola, Thomas, Ian, Johnson, Sean, Othman, Jad, Gilkes, Amanda, Russell, Nigel H., Sikorski, Adam, Ellis, Pete, Marsico, Giovanni, Jones, Greg, MacKenzie, Crystal, To, Zung, DiMartino, Jorge, Kumar, Pavan

Get full text

Abstract C064: The investigational peptide drug ALRN-6924, a dual inhibitor of MDMX and MDM2, is an effective myelopreservation agent by Carvajal, Luis A, Sutton, David, Mounir, Mariam, McClanaghan, Joseph, Guerlavais, Vincent, Aivado, Manuel, Vukovic, Vojislav, Annis, Allen

“…Abstract Aim: We investigated whether p53 activation with ALRN-6924 can prevent or reduce chemotherapy-induced hematopoietic toxicity while preserving or…”
Get full text

Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1m Patients Achieving MRD-Negative CR after Intensive Induction by Döhner, Konstanze, Döhner, Hartmut, Weber, Daniela, Kapp-Schwoerer, Silke, Gilkes, Amanda, Thomas, Ian, Johnson, Sean, Potter, Nicola, Bevan, Yana, Othman, Jad, Russell, Nigel H., Röllig, Christoph, Thiede, Christian, Bornhaeuser, Martin, Oellerich, Thomas, Elder, Jenna, Carvajal, Luis A., To, Zung, DiMartino, Jorge, Dillon, Richard

Get full text